%0 Journal Article
%T Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.
%A Zeng Z
%A Lin H
%A Jiang M
%A Yuan J
%A Li X
%A Jia Y
%A Yang L
%A Zhang H
%J Front Pharmacol
%V 15
%N 0
%D 2024
%M 39114362
%F 5.988
%R 10.3389/fphar.2024.1424606
%X The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated inflammatory bowel disease (IBD) treatment and increased medical costs. The recent expiration of patents of some anti-TNFα biologics (such as infliximab and adalimumab) facilitated the development of biosimilars. Comparable pharmacokinetic, efficacy, safety, and immunogenicity profiles between anti-TNFα originators and biosimilars were demonstrated in different studies. Anti-TNFα biosimilars hold promise for reducing the high cost of biologics and increasing patient access to biologics. In this review, we outline the current data on the use of anti-TNFα originators and biosimilars in patients with IBD, with a focus on the efficacy, safety, and immunogenicity profiles of infliximab and adalimumab biosimilars. The potential benefits, challenges, and future directions of anti-TNFα biosimilars are also discussed in the review.